6:29 PM
Nov 05, 2012
 |  BC Extra  |  Clinical News

Epanova meets Phase III hypertriglyceridemia endpoints

Omthera Pharmaceuticals Inc. (Bedminster, N.J.) said once-daily 2 and 4 g doses Epanova as an add-on to statin therapy each met the primary endpoint of reducing non-HDL-C from baseline to week six vs. active control in the Phase III ESPIRIT trial to treat hypertriglyceridemia. Specifically, 2 g Epanova reduced non-HDL-C by 4% (p<0.05) and 4 g Epanova reduced non-HDL-C by...

Read the full 289 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >